Literature DB >> 8141427

Achalasia. A morphologic study of 42 resected specimens.

J R Goldblum1, R I Whyte, M B Orringer, H D Appelman.   

Abstract

Achalasia is characterized by failure of relaxation of the lower esophageal sphincter and absence of progressive peristalsis in the esophageal body. Few data are available regarding the morphologic features of achalasia, in particular its histologic progression. The esophagi of 42 patients with achalasia treated with total thoracic esophagectomy were examined histologically in order to systematically identify morphologic features of clinically unresponsive achalasia and to determine what could be learned about the disease's evolution. In all cases, myenteric ganglion cells within the esophageal body were markedly diminished, with 20 specimens having none. Twenty specimens had residual ganglion cells in the proximal esophagus, and 15 specimens had a few randomly distributed ganglion cells in the mid- and distal portions of the esophagus. Inflammation within myenteric nerves, present in all cases, generally consisted of a mixture of lymphocytes and eosinophils, occasionally with plasma and mast cells. Focal replacement of myenteric nerves by collagen occurred in all cases, and there was almost complete replacement in several cases. Actual destruction of the residual ganglion cells was not seen. The resected esophagi also shared extramyenteric morphologic features. Some features probably stemmed from physiologic obstruction, such as muscular hypertrophy, mainly of the muscularis propria (all cases), with secondary degeneration and fibrosis (29 cases), and eosinophilia of the muscularis propria (22 cases). Other changes, probably resulting from chronic stasis of ingested materials in the lumen, included diffuse squamous hyperplasia (all cases), lymphocytic mucosal esophagitis (28 cases), lymphocytic inflammation of the lamina propria and submucosa with prominent germinal centers (all cases), and submucosal periductal or glandular inflammation with complete loss of submucosal glands in half of the cases. One patient had high-grade squamous dysplasia, and another had superficially invasive squamous cell carcinoma. A third group of changes was probably due to previous esophagomyotomy, including abnormal gastroesophageal reflux, as shown by pH reflux testing (13 cases) and Barrett's mucosa (four cases). In one case of Barrett's there was low-grade dysplasia. Clinically unresponsive, surgically resected achalasia has almost total loss of ganglion cells, and widespread destruction of myenteric nerves has already occurred. The only active component is myenteric inflammation. However, it cannot be determined whether this inflammation is a manifestation of ongoing nerve destruction or whether it is a secondary phenomenon.

Entities:  

Mesh:

Year:  1994        PMID: 8141427

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  77 in total

Review 1.  Pharmacotherapy for the management of achalasia: Current status, challenges and future directions.

Authors:  Ammar Nassri; Zeeshan Ramzan
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-11-06

2.  Possible new endoscopic finding in patients with achalasia: "Gingko leaf sign".

Authors:  Yoshimasa Hoshikawa; Shintaro Hoshino; Noriyuki Kawami; Tomohide Tanabe; Yuriko Hanada; Nana Takenouchi; Osamu Goto; Mitsuru Kaise; Katsuhiko Iwakiri
Journal:  Esophagus       Date:  2019-06-21       Impact factor: 4.230

3.  Robotic-assisted Heller myotomy versus laparoscopic Heller myotomy for the treatment of esophageal achalasia: a case-control study.

Authors:  Alexis Sánchez; Omaira Rodríguez; Elias Nakhal; Hugo Davila; Rair Valero; Renata Sánchez; Romina Pena; Maria F Visconti
Journal:  J Robot Surg       Date:  2011-07-08

4.  A utility of peroral endoscopic myotomy (POEM) across the spectrum of esophageal motility disorders.

Authors:  Toshitaka Hoppo; Shyam J Thakkar; Lana Y Schumacher; Yoshihiro Komatsu; Steve Choe; Amit Shetty; Sara Bloomer; Emily J Lloyd; Ali H Zaidi; Mathew A VanDeusen; Rodney J Landreneau; Abhijit Kulkarni; Blair A Jobe
Journal:  Surg Endosc       Date:  2015-04-07       Impact factor: 4.584

5.  Epidemiological analysis of achalasia in Japan using a large-scale claims database.

Authors:  Hiroki Sato; Hiroshi Yokomichi; Kazuya Takahashi; Kentaro Tominaga; Takeshi Mizusawa; Naruhiro Kimura; Yuzo Kawata; Shuji Terai
Journal:  J Gastroenterol       Date:  2019-01-03       Impact factor: 7.527

6.  Serum from achalasia patients alters neurochemical coding in the myenteric plexus and nitric oxide mediated motor response in normal human fundus.

Authors:  S Bruley des Varannes; J Chevalier; S Pimont; J-C Le Neel; M Klotz; K-H Schafer; J-P Galmiche; M Neunlist
Journal:  Gut       Date:  2005-08-16       Impact factor: 23.059

Review 7.  Neurology and the gastrointestinal system.

Authors:  G D Perkin; I Murray-Lyon
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-09       Impact factor: 10.154

8.  Long-term outcome of peroral endoscopic myotomy for esophageal achalasia in patients with previous Heller myotomy.

Authors:  Helle Ø Kristensen; Jakob Kirkegård; Daniel Willy Kjær; Frank Viborg Mortensen; Rastislav Kunda; Niels Christian Bjerregaard
Journal:  Surg Endosc       Date:  2016-10-03       Impact factor: 4.584

9.  Achalasia combined with esophageal cancer treated by concurrent chemoradiation therapy.

Authors:  Jun Chul Park; Yong Chan Lee; Sang Kyum Kim; Yu Jin Kim; Sung Kwan Shin; Sang Kil Lee; Hoguen Kim; Choong Bai Kim
Journal:  Gut Liver       Date:  2009-12-31       Impact factor: 4.519

Review 10.  A controversy that has been tough to swallow: is the treatment of achalasia now digested?

Authors:  Garrett R Roll; Charlotte Rabl; Ruxandra Ciovica; Sofia Peeva; Guilherme M Campos
Journal:  J Gastrointest Surg       Date:  2009-09-17       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.